37 results about "Transcriptional expression" patented technology

This invention relates to the fields of molecular biology and biomedicine, and discloses siRNA for the expression of the *Schistosoma japonicum* Hsc20 gene and its applications. The siRNA contains a nucleotide sequence that hybridizes to a target sequence of the *Schistosoma japonicum* Hsc20 gene, wherein the target sequence is selected from the sequences shown in SEQ ID NO. 1-SEQ ID NO. 4. The siRNA specifically inhibiting the expression of the *Schistosoma japonicum* Hsc20 gene provided by this invention can be used to interfere with the transcription and expression of the *Schistosoma japonicum* Hsc20 gene and the growth and development of *Schistosoma japonicum*. In vitro experiments have confirmed that the siRNA provided by this invention can efficiently silence the *SjHsc20* gene; and in vivo RNA interference experiments in mice show that this siRNA can induce 50.62% (…) P The insect reduction rate was <0.05% and 44.29% ( P A liver oocyte reduction rate of <0.01% is suitable for preparing drugs to treat schistosomiasis.

The present application relates to the field of agricultural biotechnology, in particular to a bidirectional promoter derived from Myceliopthora thermophila and application thereof. The bidirectional promoter derived from Myceliopthora thermophila has a unique bidirectional transcription activity feature, and can simultaneously and efficiently initiate the transcription and expression of two independent genes in the same regulation region in opposite directions. The present application provides a more favorable promoter element for the metabolic engineering of the industrial filamentous fungus Myceliopthora thermophila, significantly simplifies the construction process of a multi-gene co-expression system, and realizes the synergistic expression of two functional genes through a single promoter element, which has a wide application space and market prospect in the production of enzyme preparations, biological medicine products and the like.

This invention discloses the application of a branched-chain amino acid (BCAA) restricted diet in the preparation of drugs for treating liver metastases of tumors. Through mouse model experiments, this invention found that restricting the intake of BCAAs (valine, isoleucine, and leucine) in the diet, or using the SCD1 inhibitor A939572, can significantly inhibit liver metastases of tumors, especially pancreatic cancer liver metastases. Experimental results show that a BCAA restricted diet or SCD1 inhibitor can reduce the number and volume of liver metastases and inhibit their growth. This invention also reveals its mechanism of action: BCAA restriction reduces the propionylation modification of SREBP1, downregulates the transcriptional expression of its target gene SCD1, and thus reduces lipid synthesis, thereby exerting an anti-tumor liver metastasis effect. This invention provides a novel dietary intervention strategy and drug target for the treatment of liver metastases of tumors.

The invention provides a brain glioma immune microenvironment complexity assessment method and application, and the method comprises the following steps: obtaining m glioma samples, and carrying out transcriptome determination on each cell in each glioma sample to obtain transcriptional expression profile data of the cells; carrying out clustering analysis on transcriptional expression profile data of the single cells through K-means clustering, and preliminarily identifying lymphocytes and myeloid cells according to immune cell classical markers; carrying out clustering analysis on the identified transcription expression profile data of the lymphocytes and myeloid cells, and identifying n cell subgroups; calculating the enrichment score of the characteristic gene set of each cell subset in the glioma transcriptome sample, wherein the higher the score is, the higher the enrichment proportion of the cell subset in the sample is; and evaluating the complexity of immune cell enrichment in the glioma sample based on the enrichment score of the characteristic gene set. The immune cell infiltration complexity can be predicted, and the relationship between immune cell enrichment complexity and brain glioma prognosis can be identified.

The invention relates to a method for inferring a silkworm chrysalis stage development process based on trimethyl lysine hydroxylase. The method comprises the following steps: (1) constructing a correlation model of relative transcription expression quantity of a trimethyl lysine hydroxylase gene and a reference gene of a silkworm chrysalis sample of a variety to be detected and pupal stage development time; and (2) determining the relative transcription expression quantity of the trimethyl lysine hydroxylase and the reference gene in the silkworm chrysalis to be detected, and calculating the pupal stage development time according to the correlation model obtained in the step (1). According to the method, the development process of one or more silkworm chrysalis can be accurately measured, errors caused by traditional visual inspection can be reduced, a new detection method is provided for deducing the pupal development process of the silkworms, and an important basis is provided for judging moth formation time in silkworm seed production work.

The present application provides a low-oxygen-induced promoter for yeast cells and application thereof. The promoter of the present application can achieve appropriate driving of transcription / expression of a target gene under different oxygen environments, and plays a role of driving transcription / expression with medium and high intensity.

The invention belongs to the field of gene engineering, and particularly relates to application and a method of an NtZFP26 gene in promoting nicotine synthesis. The invention finds and verifies that the tobacco C2H2 type zinc finger protein transcription factor NtZFP26 can be specifically combined with a promoter of a nicotine synthesis key gene NtQPT2, and activates the transcription expression of the nicotine synthesis key gene NtQPT2, thereby positively regulating the biosynthesis of nicotine. Experiments prove that the NtZFP26 gene specifically expressed at the root of tobacco is regulated by topping and hormones such as NAA, ABA and MeJA; knockout of the NtZFP26 gene can lead to significant reduction of tobacco nicotine content and synthesis key gene expression quantity. The invention provides a key gene target and a new technical approach for directionally regulating and controlling the nicotine content of tobacco through a genetic engineering means.

The invention discloses an application of a rice OsPHR2 gene in regulation and control of selenium bioaugmentation. The rice OsPHR2 gene is shown as SEQ ID No: 1 in a sequence table, and the amino acid sequence of the protein of the rice OsPHR2 gene is shown as SEQ ID No: 2. According to the invention, the promoter of the rice OsPHR2 is adopted to drive the rice OsPHR2 to increase one to two copy numbers in the rice body, so that the content of phosphorus in the rice body is increased without influencing the growth, development and yield of the rice by means of moderately increasing the transcription expression of the rice OsPHR2, meanwhile, the absorption and accumulation of selenium can be promoted, and the biological enrichment enhancement of rice selenium is realized.

The invention discloses a core promoter for construction of a gene expression system in mammalian cells and application of the core promoter, and provides polynucleotide with promoter activity, a transcription expression cassette containing the polynucleotide, a recombinant expression vector, a recombinant host cell and application in an expression system. The core promoter provided by the invention can be combined with various enhancers and coding sequences in a modular manner, is suitable for constructing a drug-induced expression system, a tumor specific expression system, a synthesis loop and a gene expression regulation system related to cell therapy, and has good universality and application prospects.

The application discloses a kind of preeclampsia (Preeclampsia, PE) diagnosis and treatment biology marker and its application;The application is from clinical sample, cell and in-depth demonstration of overexpressed FBP2 at the level of body, which causes the mechanism of PE occurrence by inhibiting the invasion of trophoblasts, and the application verifies that the classic gene HEY1 downstream of NOTCH3 can be combined with the promoter region of FBP2 and transcribe to inhibit the expression of FBP2, FBP2 is combined with c-MYC protein and inhibits the transcriptional activity of c-MYC, down-regulates the transcriptional expression of TFAM, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the results of pre-experiment and information analysis, is a new target for in-depth exploration of PE clinical diagnosis and treatment, and the research results can provide theoretical basis for guiding early prediction and intervention of PE in the future.

Disclosed in the present invention is a use of a 2-aminothiazole derivative in the preparation of an anti-aging drug. The 2-aminothiazole derivative can effectively alleviate microglial cell aging in vitro, reduce accumulation of senescence-associated β-galactosidase in aged cells, decrease secretion of a senescence-associated secretory phenotype, and ameliorate apoptosis and oxidative stress damage in the aged cells. In a mouse in vivo experiment, compounds A1-A10 can significantly improve aging-induced cognitive dysfunction and impairment of long-term and short-term learning and memory abilities, reduce transcriptional expression levels of pro-inflammatory factors in the brain, and alleviate neuroinflammation. In summary, the present inventors propose that 2-aminothiazole derivatives have good anti-aging efficacy and possess great application potential in anti-aging.

The application belongs to the field of medicine, and particularly relates to a synergistically treating chordoma combined drug and application thereof. The combined drug is Notch blocker PF03084014 and ELT or Notch blocker PF03084014 and DOX. Research proves that the Notch blocker PF0308401 targets and regulates the transcription expression of a key transcription regulatory factor Brachyury of chordoma, and inhibits tumor cell proliferation; and can obviously improve the drug resistance of chordoma to the chemotherapeutic drugs DOX and ELT. The application can provide an advantageous laboratory research basis and a transformation research direction for a chordoma drug treatment scheme.

This invention discloses the application of the HbCBF1 gene in regulating ethylene content in rubber trees, belonging to the field of agricultural biotechnology. By overexpressing the HbCBF1 gene (nucleotide sequence shown in SEQ ID NO.1), this invention significantly enhances the biosynthesis of ethylene in transgenic plants, manifested as an increased ethylene release rate, elevated content of the ethylene precursor ACC, and enhanced activity of key enzymes in the ethylene synthesis pathway, SAMS, ACS, and ACO. It also exhibits dwarfing phenotypes associated with excessive ethylene accumulation, including significantly reduced plant height, thinner stems, shorter internodes, and accelerated leaf senescence. Molecular mechanism studies show that HbCBF1 directly activates the transcriptional expression of SAMS1 by binding to the CRT / DRE cis-acting element in the SAMS1 gene promoter, thereby upregulating ethylene biosynthesis. This invention provides a new target gene and regulatory method for the genetic engineering improvement of rubber trees.

The invention discloses an ostrinia furnacalis nuclear receptor HR39 gene, an RNA interference fragment, dsRNA and application thereof, and relates to the field of agricultural pest control. The full-length cDNA sequence of the HR39 gene is as shown in SED ID NO: 1, the amino acid sequence of the coded protein is as shown in SED ID NO: 2, and the sequence of the RNA interference fragment is as shown in SED ID NO: 3. The full-length cDNA sequence of the HR39 gene is obtained, a dsRNA segment targeting the gene is designed, transcription expression of the HR39 gene is successfully interfered, and results show that ovary development of female individuals interfering the HR39 is remarkably inhibited, the egg laying amount and the egg hatching rate are remarkably reduced, and the reproductive capacity of the female individuals is remarkably inhibited. The HR39 gene provided by the invention provides a molecular target for designing a specific and efficient nucleic acid pesticide to inhibit reproduction of pests, and has a good application prospect in green prevention and control of ostrinia furnacalis.

This present disclosure provides compositions and methods of increasing activating transcription 4 (ATF4) expression in a subject, thereby preventing and / or treating cardiomyopathy-related diseases in the subject.

This invention discloses a graph reasoning and analysis system for addressing defects in cellular antigen processing, belonging to the field of knowledge graph reasoning technology, to solve the problem of slow interpretable localization of defect presentation. This invention constructs a detection likelihood set by integrating HLA typing, somatic cell variation, transcriptomic expression, immunopeptidomics, and surface HLA detection. It assembles direct and cross-presentation subgraphs using pattern gating and loading complex integrity rules, generating reachable paths and observation consistency matrices. It distinguishes between structural contradictions and detection limitations, performs node pruning and link contraction based on constraint propagation to form an individualized graph, and outputs defective nodes and paths based on minimum interpretable paths and causal graph cost search. It generates validation and intervention lists and clinical decision support outputs, thereby reducing unnecessary detection and intervention attempts and improving the timeliness and consistency of case analysis and strategy formulation.

The present application relates to the technical field of biological medicine, and provides a Chinese herbal medicine vesicle-LNP hybrid tumor mRNA vaccine and application thereof.The tumor mRNA vaccine is obtained by hybridizing Chinese herbal medicine nano vesicles and lipid nanoparticles loaded with tumor antigen mRNA.The present application reduces the safety risk of cationic lipid carriers by using the good biocompatibility of Chinese herbal medicine.Combined with the characteristics of Chinese herbal medicine, the nano vesicles are extracted, which promotes the LNP to more effectively target antigen presenting cells, promotes the uptake level of antigen presenting cells, enhances the phagocytosis of mRNA, and can enhance the targeting and transcription expression level of mRNA.Finally, the tumor mRNA vaccine hybridized by Chinese herbal medicine nano vesicles and LNP can strengthen the effect of inhibiting tumor progression, inhibiting tumor recurrence and inhibiting tumor metastasis after vaccination, and opens up a path for its combination with more abundant immunotherapy methods.

The invention discloses application of ammonium ferric citrate in preparation of a medicine for resisting grouper iridovirus. The effective concentration of the ammonium ferric citrate at the cellular level is 0.04-0.08 mM, and the effective concentration of the ammonium ferric citrate in vivo is 20 mg / kg. The in-vivo and in-vitro treatment of the ferric ammonium citrate can inhibit the replication of the SGIV. The ferric ammonium citrate with a safe concentration in in-vitro cells can significantly reduce cytopathy induced by SGIV infection and reduce viral protein expression and yield of progeny viruses, intraperitoneal injection of ferric ammonium citrate can inhibit transcription expression of viral genes in vivo, reduce the death rate of groupers caused by SGIV infection, and improve the safety of the groupers. The ferric ammonium citrate has a remarkable antiviral effect and has the potential of researching and developing the anti-iridovirus medicine. In addition, the ferric ammonium citrate can improve the oxidation resistance of cells or tissues, so that tissue pathological damage caused by virus infection is improved. As an antiviral drug, the ammonium ferric citrate has a certain application value in prevention and control of grouper iridovirus diseases.

This present disclosure provides compositions and methods of increasing activating transcription 4 (ATF4) expression in a subject, thereby preventing and / or treating cardiomyopathy-related diseases in the subject.

The invention discloses a cattle ACSS1 gene promoter as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence of the cattle ACSS1 gene promoter disclosed by the invention is any one sequence of ACSSI1-A-ACSS1-F as shown in SEQ ID NO.1-6. The invention further discloses a preparation method of the cattle ACSS1 gene promoter. Experiments find that the promoters ACSS1-B, ACSS1-C, ACSS1-D and ACSS1-E have obvious promoter activity in human mammary epithelial cells MAC-T, which is of great significance for revealing a regulatory mechanism of bovine ACSS1 transcriptional expression, verifying a high-quality beef cattle breeding scheme of a targeted bovine ACSS1 expression level and developing a new eukaryotic protein expression system. And the method can also be used for cell level screening of drugs for targeting bovine ACSS1 expression.

This invention relates to the field of biomedical technology, and more particularly to the use of a combination of RVX208 and temozolomide for the treatment of glioblastoma. It also relates to the use of RVX208 to resensitize temozolomide-resistant cancers to temozolomide treatment. The use of at least one of RVX208, a pharmaceutically acceptable salt of RVX208, a solvate of RVX208, a hydrate of RVX208, a polymorph of RVX208, an isomer of RVX208, a prodrug form of RVX208, and temozolomide in the preparation of a glioblastoma therapeutic agent. RVX208 inhibits the transcriptional activity of various genes related to cell cycle progression and proliferation maintenance by inhibiting BET family proteins or other target molecules, leading to cell cycle arrest, inhibition of cell proliferation, and induction of programmed cell death. RVX208 also interferes with the transcriptional expression of genes related to mitochondrial homeostasis regulation, resulting in a decrease in mitochondrial membrane potential and reduced ATP production, thus enabling RVX208 to disrupt mitochondrial function in GBM cells and produce a synergistic antitumor effect with temozolomide.

The application of JIB-04 in the preparation of a drug for treating pulmonary alveolar proteinosis relates to the technical field of biological medicine. Based on the epigenetic mechanism that menin in macrophages promotes the transcription and expression of GM-CSF through H3K36m3, and maintains the activation of alveolar macrophages and the homeostasis of alveolar surfactant, it is proved that the clinical application prospect of the small molecule inhibitor JIB-04 targets to improve the H3K36m3 modification in macrophages and the expression of GM-CSF for treating PAP. JIB-04 can effectively restore the chromatin H3K36m3 modification level and GM-CSF transcription caused by Men1 deletion, and restore the differentiation and function of damaged macrophages. Important theoretical and data support is provided for the application of JIB-04 in the targeted treatment of clinical PAP.

Methods for single-cell DNA methylation profiling are disclosed herein, with embodiments featuring use of droplet-based cell barcoding and conversion reagents to generate high-quality methylomes and / or methylome-plus-transcriptomes, for single cell genomic analysis and correlation of methylation state with transcript expression levels at single-cell resolution. The present disclosure is based, at least in part, upon discovery of methods and compositions capable of leveraging cell barcoding and conversion reagents to generate high-quality single-cell methylomes capable of being assessed rapidly in parallel across populations of cells, as well as coordinated single-cell methylome-plus-transcriptomes formatted for parallel, high-throughput assessment of cellular populations with precise single-cell resolution.

The invention discloses a constitutive promoter library and application, and relates to a construction method of a bacillus methylophilus promoter library, polynucleotide with promoter activity, a promoter mutant library containing the polynucleotide with the promoter activity, a transcription expression cassette, a recombinant expression vector and a recombinant host cell. And a method for producing a target compound. The invention firstly provides the construction method of the bacillus methylolmethane promoter library, a series of promoter mutants can be obtained through the method, the promoter mutants cover a wide expression intensity range and are wide in universality, and abundant promoter elements are provided for modification of target genes.

The application discloses a biomarker for predicting recurrence of chronic rhinosinusitis and application thereof, and the biomarker is CASP3 and / or CHMP7. The biomarker CASP3 and CHMP7 gene has high transcription expression in recurrent chronic rhinosinusitis, is a potential recurrence diagnosis marker, is used for diagnosis and prediction of recurrence states of all types of chronic rhinosinusitis, more accurately judges whether rhinosinusitis recurs or not, effectively reduces misdiagnosis rate and missed diagnosis rate, and provides a new perspective and tool for early diagnosis of diseases.

The invention belongs to the field of biological pharmacy, and relates to a herbal hydrogel delivery system and a preparation method and application thereof. The invention successfully constructs and systematically verifies a herbaceous hydrogel delivery system (Rh-Gel at CCM at PM) with cartilage targeting, the platform efficiently delivers BRD4 PROTAC through mesoporous silicon nanoparticles (PM) coated with cartilage cell membrane (CCM), and the degradation of BRD4 is remarkably promoted, so that the histone acetylation activation of Nav1.7 is inhibited, and the transcriptional expression of Nav1.7 is regulated and controlled. The mechanism effectively improves the inflammation, catabolism enhancement and mitochondrial dysfunction of cartilage cells induced by TNF-alpha, recovers anabolism and energy steady state, and finally significantly relieves cartilage degeneration and joint dysfunction in a DMM and MIA induced OA mouse model.

This invention discloses a sugarcane gene ScJAZ10 The sugarcane gene and its application in regulating plant flowering relate to the field of plant biotechnology. ScJAZ10 The nucleotide sequence of the protein is shown in SEQ ID No. 1, and the amino acid sequence of the protein it encodes is shown in SEQ ID No. 2. This invention reveals for the first time that the ScJAZ10 protein can act as an atypical transcriptional coactivator, physically interacting with the ScNAC23 transcription factor in the cell nucleus to form a protein complex, synergistically activating the downstream core florigen gene. ScFT Gibberellin (GA) can activate transcription, thereby promoting earlier flowering in plants. ScJAZ10 The ScJAZ10 protein is transcribed and expressed, and its flowering-promoting function depends on the accumulation of endogenous GA. This invention breaks through the traditional understanding that JAZ proteins are only transcriptional repressors, providing new key gene targets and molecular regulatory modules for the genetic improvement of flowering time in sugarcane and other plants, and has significant theoretical value and broad application prospects.

The invention relates to the field of molecular biology and biological medicine, and discloses a schistosoma japonicum Hsc20 gene expressed siRNA and application thereof, the siRNA contains a nucleotide sequence hybridized with a target sequence of the schistosoma japonicum Hsc20 gene, and the target sequence is selected from sequences shown as SEQ ID NO.1-SEQ ID NO.4. The invention also discloses a preparation method of the schistosoma japonicum Hsc20 gene expressed siRNA. The siRNA for specifically inhibiting the expression of the schistosoma japonicum Hsc20 gene, provided by the invention, can be used for interfering the transcription and expression of the schistosoma japonicum Hsc20 gene and the growth and development of schistosoma japonicum; in-vitro experiments prove that the siRNA provided by the invention can be used for efficiently silencing the SjHsc20 gene; in-vivo RNA interference test results of mice show that the siRNA can induce the mice to obtain 50.62% (Plt; 0.05) and an insect reduction rate of 44.29% (Plt; 0.01), and is suitable for preparing the medicine for treating the schistosomiasis.

The application discloses application of Rv-NG-14 gene and coded protein thereof as a multidrug-resistant tuberculosis biomarker, the nucleotide sequence of the gene is SEQ ID NO:1, and the amino acid sequence of the coded protein is SEQ ID NO:2. The gene is verified to be normally expressed in Mycobacterium tuberculosis through multi-omics verification, and it is found through detection of 50 clinical strains that the transcriptional expression level of the gene in a multidrug-resistant group is significantly lower than that in a drug-sensitive group (p=0.002), and there is no significant difference between a single drug-resistant group and the drug-sensitive group. The application first finds out the multidrug-resistant tuberculosis marker value of the gene, and the gene can be used for preparing products such as detection kits and test strips, so that rapid diagnosis of multidrug-resistant tuberculosis is realized, a new target point is provided for research and development and screening of anti-multidrug-resistant tuberculosis drugs, and the application prospect is wide in clinical application.